Carl Morrow
Overview
Explore the profile of Carl Morrow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
830
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zurcher K, Riou J, Morrow C, Ballif M, Koch A, Bertschinger S, et al.
J Infect Dis
. 2022 Jan;
225(9):1642-1652.
PMID: 35039860
Background: Congregate settings, such as healthcare clinics, may play an essential role in Mycobacterium tuberculosis (Mtb) transmission. Using patient and environmental data, we studied transmission at a primary care clinic...
2.
Dinkele R, Gessner S, McKerry A, Leonard B, Seldon R, Koch A, et al.
PLoS Pathog
. 2021 Feb;
17(2):e1009262.
PMID: 33524021
Interrupting transmission is an attractive anti-tuberculosis (TB) strategy but it remains underexplored owing to our poor understanding of the events surrounding transfer of Mycobacterium tuberculosis (Mtb) between hosts. Determining when...
3.
Patterson B, Dinkele R, Gessner S, Morrow C, Kamariza M, Bertozzi C, et al.
PLoS One
. 2020 Sep;
15(9):e0238193.
PMID: 32881875
Introduction: Detection of Mycobacterium tuberculosis (Mtb) in patient-derived bioaerosol is a potential tool to measure source case infectiousness. However, current bioaerosol sampling approaches have reported low detection yields in sputum-positive...
4.
Zurcher K, Morrow C, Riou J, Ballif M, Koch A, Bertschinger S, et al.
BMJ Open
. 2020 Aug;
10(8):e036214.
PMID: 32847906
Introduction: Tuberculosis (TB) transmission is difficult to measure, and its drivers are not well understood. The effectiveness of infection control measures at healthcare clinics and the most appropriate intervention strategies...
5.
Penn-Nicholson A, Mbandi S, Thompson E, Mendelsohn S, Suliman S, Chegou N, et al.
Sci Rep
. 2020 May;
10(1):8629.
PMID: 32451443
Improved tuberculosis diagnostics and tools for monitoring treatment response are urgently needed. We developed a robust and simple, PCR-based host-blood transcriptomic signature, RISK6, for multiple applications: identifying individuals at risk...
6.
Patterson B, Morrow C, Singh V, Moosa A, Gqada M, Woodward J, et al.
Gates Open Res
. 2019 Sep;
1:11.
PMID: 29355225
: Tuberculosis (TB) is predominantly an airborne disease. However, quantitative and qualitative analysis of bio-aerosols containing the aetiological agent, , has proven very challenging. Our objective is to sample bio-aerosols...
7.
McCreesh N, Morrow C, Middelkoop K, Wood R, White R
Epidemics
. 2019 Mar;
28:100339.
PMID: 30910644
Introduction: Age-mixing patterns can have substantial effects on infectious disease dynamics and intervention effects. Data on close contacts (people spoken to and/or touched) are often used to estimate age-mixing. These...
8.
Revell A, Khabo P, Ledwaba L, Emery S, Wang D, Wood R, et al.
South Afr J HIV Med
. 2018 Mar;
17(1):450.
PMID: 29568609
Background: Selecting the optimal combination of HIV drugs for an individual in resource-limited settings is challenging because of the limited availability of drugs and genotyping. Objective: The evaluation as a...
9.
Hella J, Morrow C, Mhimbira F, Ginsberg S, Chitnis N, Gagneux S, et al.
J Infect
. 2017 Jul;
75(3):191-197.
PMID: 28676410
Objectives: For tuberculosis (TB) transmission to occur, an uninfected individual must inhale the previously infected breath. Our objective was to identify potential TB transmission hotspots in metropolitan city of Dar...
10.
Revell A, Wang D, Wood R, Morrow C, Tempelman H, Hamers R, et al.
J Antimicrob Chemother
. 2016 Jun;
71(10):2928-37.
PMID: 27330070
Objectives: Optimizing antiretroviral drug combination on an individual basis in resource-limited settings is challenging because of the limited availability of drugs and genotypic resistance testing. Here, we describe our latest...